104985Development of attenuated bovine herpesvirus-4 as a safe, inexpensive, single dose vaccine to control Streptococcus suis infection in domestic pigsClosedCollaborative R&DInnovate UKVaccines are one of medicine's greatest triumphs, having led to the virtual eradication of several deadly bacterial diseases. However, most vaccines in use today were developed by techniques pioneered over 100 years ago and do not represent the full potential of the field. Bovine herpes virus vaccines (BoHV-4) are one of the most promising classes of new vaccines, combining durability of immunity with low costs of manufacture. In this project, we will develop a novel BoHV-4 vaccine against S. suis - a major disease affecting pig farmers worldwide and a dangerous zoonotic pathogen in humans. The applicants will develop the novel vaccine using immunogenic S. suis proteins and then test it in pigs to convincingly demonstrate both efficacy and a quantifiable reduction in antibiotic usage. Our objectives are firstly to commercialize the vaccine within 3 years post-project and secondly establish it as a flagship product within our powerful BoHV-4 platform which can be targeted at many other serious bacterial infections affecting both animal and human health. The project is innovative in that there are currently no effective vaccines for the treatment and prevention of S. suis in pigs